FINANCIAL TIMES: Johnson & Johnson will pay $70m to US regulators in the first of what is set to be a series of prosecutions of the pharmaceutical industry under the Foreign Corrupt Practices Act…
Details of the medical device payments – which J&J voluntarily disclosed to US regulators in 2007 – also come at an awkward time for European governments, highlighting concerns over corruption in eastern and southern nations that have added to the eurozone’s financial problems…
A growing number of criminal and civil actions have imposed substantial fines on drug companies in recent years for aggressive marketing practices, including an $81m settlement reached by two J&J subsidiaries last year for marketing its epilepsy drug Topamax for unapproved uses… (more)
